Actuate Therapeutics announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in...
Read more
Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that the Company will be added to the Russell 2000® Index as part...
Read more
Actuate Therapeutics, Inc. has received Rare Pediatric Disease Designation from the FDA for elraglusib, a novel GSK-3β inhibitor being...
Read more
Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...
Read more
Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking...
Read more
Actuate Therapeutics, Inc., rang the Nasdaq opening bell in celebration of their IPO. This marks the start of an...
Read more
Actuate Therapeutics, Inc. (Nasdaq: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high...
Read more
Actuate Therapeutics (ACTU) plans to raise $50 million in an initial public offering on the week of June 24th,...
Read more
Actuate Therapeutics plans to sell nearly 5.56 million shares at between $8 and $10 apiece in its initial public...
Read more
Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with...
Read more